3D graphic showing blood cells passing CD34 beads for enrichment of CD34+ cells in graft engineering
3D graphic showing blood cells passing CD34 beads for enrichment of CD34+ cells in graft engineering
Logo

Hematopoietic stem cell enrichment in graft engineering

Enrich CD34+ hematopoietic stem cells (HSCs) and passively deplete unwanted cells for autologous and allogeneic hematopoietic stem cell transplantation (HSCT). Leverage the CliniMACS Prodigy® Platform and CliniMACS® Plus System to generate CD34+ stem cell products of up to 95% purity and with up to a 4.5 log10 depletion of T cells. The enriched product is ideal for HSCT or further engineering.1

Overcoming treatment challenges with high-purity grafts

The effective and simultaneous passive depletion of T cells during CD34+ enrichment on the CliniMACS Prodigy Platform and CliniMACS Plus System provide highly pure populations of HSCs used as stem cell grafts in various transplantation settings. The following are examples of current applications.

Graft-versus-host disease (GVHD) prophylaxis
Enriched CD34+ cells were used as a GVHD prevention strategy in HLA-identical allogeneic HSCT to treat adult acute myeloid leukemia (AML) in first complete remission.2 Adding memory T cells to the graft supports immune reconstitution and significantly improves non-relapse mortality compared to pure CD34+ stem cell grafts while maintaining excellent GVHD prevention.3,4

Stem cell boost (SCB) – rescue option for poor graft function (PGF) and long-term cytopenia after CAR T cell therapy
Up to a quarter of allogeneic HSCT cases are complicated by infections, bleeding, and organ failure due to PGF.5 A boost of enriched CD34+ stem cells has shown rapid and sustained recovery with low rates of GVHD, plus improved overall survival rates after 3 years6–12 and improved immune reconstitution.13 Researchers are also exploring stem cell boost treatments to prevent PGF in other transplantation contexts.14,15
Long-term cytopenia is a severe side effect after CAR T cell therapy, and SCB with selected CD34+ cells has been used as a treatment option in this setting. 16,17,32,33

The haplo-cord approach
Combined haplo-cord HSCT uses CD34+ stem cells to bridge the gap between transplant and primary engraftment of a cord blood graft. The haploidentical enriched CD34+ cells are transplanted concurrently with cord blood grafts and have led to sustained primary engraftment even with cord blood units containing very low stem cell numbers.18–20

CD34+ cell enrichment in autologous HSCT
CD34+ cell-enriched grafts are also used for HSCT in some early childhood tumors21,22, non-Hodgkin lymphoma, and other diseases in adults23,24. The technique is also used to deplete autoreactive cells from HSC grafts for autoimmune diseases like systemic lupus erythematosus and systemic sclerosis25–27.

Brochure

CliniMACS Technology in stem cell transplantation

Discover the CliniMACS Systems for GMP-compliant cell depletion and enrichment strategies that help clinicians overcome graft-versus-host disease, infections, and poor graft function.

Generate high-purity CD34+ HSCs in three automated workflow steps

Workflow overview of the CD34+ cell enrichment process on the CliniMACS Prodigy Platform and the CliniMACS Plus System.

CD34+ HSCs collected by leukapheresis are initially washed and labeled with magnetic bead-conjugated antibodies that specifically bind to the CD34 marker on the surface of target stem cells. The CliniMACS Prodigy automates all washing and labeling steps, whereas the CliniMACS Plus process requires manual handling of these steps.

The cells are then processed through the cell separation column of the CliniMACS Instruments. The magnetic field retains CD34+ cells within the column, while unlabeled cells are allowed to pass through and are discarded. Once the separation is complete, the magnetic field is removed to release the captured CD34+ cells, which are collected in a designated target cell bag, yielding a highly enriched population of CD34+ stem cells ready for downstream applications or therapeutic use.

Additionally, the CliniMACS Prodigy LP-34-(320) Process offers the option to store cells for up to 16 hours under cooled, controlled conditions. This allows for a convenient overnight cell separation run and a flexible process end time.

Video

How to enrich CD34+ hematopoietic stem cells from blood products using CliniMACS Technology?

The automated and closed process of the CliniMACS Prodigy and CliniMACS Plus Instrument enables sterile, reproducible and GMP-compliant cell enrichment.

Beyond HSC enrichment: gene engineering and active graft design

In addition to their use as highly pure graft material for HSCT, enriched CD34+ HSCs are a starting point for further cell processing. The HSCs are used in the manufacture of cells modified via gene engineering to treat specific blood disorders.28 Alternatively, the starting material can be actively adapted by specifically removing unwanted cell populations and retaining cells that support therapeutic goals.

3D graphic showing human hematopoietic stem cells originating from bone marrow

Manufacturing of gene-engineered HSCs

Viral transduction enables altering CD34+ HSCs to treat inherited disorders affecting the constitution or performance of blood, such as sickle cell anemia or primary immunodeficiencies.29–31 In the first step, CD34+ HSCs are enriched on the CliniMACS Prodigy Platform or CliniMACS Plus System. Subsequent transduction and harvesting of engineered HSCs are then conducted on the CliniMACS Prodigy Platform.

Learn more about the whole workflow

3D graphic showing blood cells passing CD34 beads for enrichment of CD34+ cells in graft engineering

Precise graft engineering via active T cell depletion

The targeted removal of unwanted cells is a form of graft engineering that retains therapeutically beneficial cell combinations within a graft. Well-defined populations of T cells are actively depleted and, depending on the depletion strategy, the resulting graft contains HSCs, other progenitor cells, natural killer (NK) cells, monocytes, dendritic cells, and desirable T cells that facilitate engraftment and may help to prevent GVHD.

Explore our T cell depletion strategies

Selected references: Learn how CliniMACS Instruments support graft engineering in HSCT

Icon selected references in turquoise

Stay up to date with influential publications across major graft engineering topics, from haploidentical and matched HSCT to stem cell boost, infections, and separation process performance.

Get personalized support on stem cell enrichment in graft engineering

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.

You have previously chosen International as your location.
What do you want to do?